Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christine Walton is active.

Publication


Featured researches published by Christine Walton.


Health Technology Assessment | 2016

The feasibility of determining the effectiveness and cost-effectiveness of medication organisation devices compared with usual care for older people in a community setting: systematic review, stakeholder focus groups and feasibility randomised controlled trial

Debi Bhattacharya; Clare F Aldus; Garry Barton; Christine Bond; Sathon Boonyaprapa; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Charlotte Salter; Lee Shepstone; Christine Walton; Steve Watson; David Wright

BACKGROUND Medication organisation devices (MODs) provide compartments for a patients medication to be organised into the days of the week and the recommended times the medication should be taken. AIM To define the optimal trial design for testing the clinical effectiveness and cost-effectiveness of MODs. DESIGN The feasibility study comprised a systematic review and focus groups to inform a randomised controlled trial (RCT) design. The resulting features were tested on a small scale, using a 2 × 2 factorial design to compare MODs with usual packaging and to compare weekly with monthly supply. The study design was then evaluated. SETTING Potential participants were identified by medical practices. PARTICIPANTS Aged over 75 years, prescribed at least three solid oral dosage form medications, unintentionally non-adherent and self-medicating. Participants were excluded if deemed by their health-care team to be unsuitable. INTERVENTIONS One of three MODs widely used in routine clinical practice supplied either weekly or monthly. OBJECTIVES To identify the most effective method of participant recruitment, to estimate the prevalence of intentional and unintentional non-adherence in an older population, to provide a point estimate of the effect size of MODs relative to usual care and to determine the feasibility and acceptability of trial participation. METHODS The systematic review included MOD studies of any design reporting medication adherence, health and social outcomes, resource utilisation or dispensing or administration errors. Focus groups with patients, carers and health-care professionals supplemented the systematic review to inform the RCT design. The resulting design was implemented and then evaluated through questionnaires and group discussions with participants and health-care professionals involved in trial delivery. RESULTS Studies on MODs are largely of poor quality. The relationship between adherence and health outcomes is unclear. Of the limited studies reporting health outcomes, some reported a positive relationship while some reported increased hospitalisations associated with MODs. The pre-trial focus groups endorsed the planned study design, but suggested a minimum recruitment age of 50-60 years. A total of 35.4% of patients completing the baseline questionnaire were excluded because they already used a MOD. Active recruitment yielded a higher consent rate, but passive recruitment was more cost-effective. The prevalence of intentional non-adherence was 24.7% [n = 71, 95% confidence interval (CI) 19.7% to 29.6%] of participants. Of the remaining 76 participants, 46.1% (95% CI 34.8% to 57.3%) were unintentionally non-adherent. There was no indication of a difference in adherence between the study arms. Participants reported a high level of satisfaction with the design. Five adverse/serious adverse events were identified in the MOD study arms and none was identified in the control arms. There was no discernible difference in health economic outcomes between the four study arms; the mean intervention cost was £20 per month greater for MOD monthly relative to usual supply monthly. CONCLUSIONS MOD provision to unintentionally non-adherent older people may cause medication-related adverse events. The primary outcome for a definitive MOD trial should be health outcomes. Such a trial should recruit patients by postal invitation and recruit younger patients. FUTURE WORK A study examining the association between MOD initiation and adverse effects is necessary and a strategy to safely introduce MODs should be explored. A definitive study testing the clinical effectiveness and cost-effectiveness of MODs is also required. STUDY REGISTRATION Current Controlled Trials ISRCTN 30626972 and UKCRN 12739. FUNDING This project was funded by National Institute for Health Research (NIHR) Health Technology Assessment Programme and will be published in full in Health Technology Assessment; Vol. 20, No. 50. See the NIHR Journals Library website for further project information.


Archive | 2016

Randomised controlled trial

Debi Bhattacharya; Clare F Aldus; Garry Barton; Christine Bond; Sathon Boonyaprapa; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Charlotte Salter; Lee Shepstone; Christine Walton; Steve Watson; David Wright


British Journal of Clinical Pharmacology | 2014

Adherence to UK national guidance for discharge information: an audit in primary care

Eman A. Hammad; David Wright; Christine Walton; Ian Nunney; Debi Bhattacharya


Archive | 2014

Do not initiate medication organisation devices without prior detailed medication review and vigilant monitoring

Debi Bhattacharya; Charlotte Salter; Clare F Aldus; Garry Barton; Christine Bond; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Lee Shepstone; Christine Walton; David Wright


Archive | 2016

Cost-effectiveness of different recruitment strategies

Debi Bhattacharya; Clare F Aldus; Garry Barton; Christine Bond; Sathon Boonyaprapa; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Charlotte Salter; Lee Shepstone; Christine Walton; Steve Watson; David Wright


Archive | 2016

Letter of thanks to participants

Debi Bhattacharya; Clare F Aldus; Garry Barton; Christine Bond; Sathon Boonyaprapa; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Charlotte Salter; Lee Shepstone; Christine Walton; Steve Watson; David Wright


Archive | 2016

Administration form 2

Debi Bhattacharya; Clare F Aldus; Garry Barton; Christine Bond; Sathon Boonyaprapa; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Charlotte Salter; Lee Shepstone; Christine Walton; Steve Watson; David Wright


Archive | 2016

Technical specifications for electronic adherence monitoring systems

Debi Bhattacharya; Clare F Aldus; Garry Barton; Christine Bond; Sathon Boonyaprapa; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Charlotte Salter; Lee Shepstone; Christine Walton; Steve Watson; David Wright


Archive | 2016

Patient consent form for randomised controlled trial

Debi Bhattacharya; Clare F Aldus; Garry Barton; Christine Bond; Sathon Boonyaprapa; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Charlotte Salter; Lee Shepstone; Christine Walton; Steve Watson; David Wright


Archive | 2016

Review of the randomised controlled trial design

Debi Bhattacharya; Clare F Aldus; Garry Barton; Christine Bond; Sathon Boonyaprapa; Ian S Charles; Robert Fleetcroft; Richard Holland; Christina Jerosch-Herold; Charlotte Salter; Lee Shepstone; Christine Walton; Steve Watson; David Wright

Collaboration


Dive into the Christine Walton's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Clare F Aldus

University of East Anglia

View shared research outputs
Top Co-Authors

Avatar

Garry Barton

University of East Anglia

View shared research outputs
Top Co-Authors

Avatar

Lee Shepstone

University of East Anglia

View shared research outputs
Top Co-Authors

Avatar

Richard Holland

University of East Anglia

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge